RhumbLine Advisers
ACHL

RhumbLine Advisers’s Achilles Therapeutics ACHL Stock Holding History

RhumbLine Advisers’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.63K Hold
4,480
– – ﹤0.01% 3848
2025
Q4 		$6.63K Hold
4,480
– – ﹤0.01% 3904
2025
Q3 		$6.63K Hold
4,480
– – ﹤0.01% 3896
2025
Q2 		$6.63K Hold
4,480
– – ﹤0.01% 3903
2025
Q1 		$6.63K Hold
4,480
– – ﹤0.01% 3880
2024
Q4 		$5.11K Hold
4,480
– – ﹤0.01% 3954
2024
Q3 		$4.57K Hold
4,480
– – ﹤0.01% 3989
2024
Q2 		$3.65K Buy
4,480
+966
+27% +$849 ﹤0.01% 4128
2024
Q1 		$4.39K Buy
+3,514
New +$3.79K ﹤0.01% 3996

Other funds holding ACHL

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

RhumbLine Advisers's ACHL Position: Q1 2026 in Review

RhumbLine Advisers held its Achilles Therapeutics (ACHL) position steady in Q1 2026 at 4,480 shares worth $6.63K. The position accounts for ﹤0.01% of the portfolio, ranked #3848.

RhumbLine Advisers first reported a position in ACHL in Q1 2024 and has held it in 9 quarters since. 3 funds tracked by Wall St. Rank hold ACHL as of Q1 2026.

  • RhumbLine Advisers held 4,480 shares of Achilles Therapeutics worth $6.63K as of Q1 2026.
  • RhumbLine Advisers left its Achilles Therapeutics share count unchanged in Q1 2026.
  • Achilles Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3848 holding.
  • RhumbLine Advisers first reported a position in Achilles Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 3 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.